Association of Obesity, Diabetes, and Alcohol Use with Liver Fibrosis among US Adults with Hepatitis C Virus Infection

Alexandra L. Migdal; Ram Jagannathan; Emad Qayed; Kenneth Cusi; Rozalina G. McCoy; Francisco J. Pasquel; Lesley S. Miller

doi:10.1001/jamanetworkopen.2021.42282

Association of Obesity, Diabetes, and Alcohol Use with Liver Fibrosis among US Adults with Hepatitis C Virus Infection

Alexandra L. Migdal, Ram Jagannathan, Emad Qayed, Kenneth Cusi, Rozalina G. McCoy, Francisco J. Pasquel, Lesley S. Miller

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Article number	e2142282
Journal	JAMA Network Open
Volume	5
Issue number	3
DOIs	https://doi.org/10.1001/jamanetworkopen.2021.42282
State	Published - Mar 18 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1001/jamanetworkopen.2021.42282

Cite this

@article{d6617822ee6d44318642335ead31afd9,

title = "Association of Obesity, Diabetes, and Alcohol Use with Liver Fibrosis among US Adults with Hepatitis C Virus Infection",

author = "Migdal, {Alexandra L.} and Ram Jagannathan and Emad Qayed and Kenneth Cusi and McCoy, {Rozalina G.} and Pasquel, {Francisco J.} and Miller, {Lesley S.}",

note = "Funding Information: Funding/Support: Dr Cusi was partially supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grants R01DK120331 and 1U01DK108320. Dr McCoy was partially supported by NIDDK grants K23DK114497, P30DK111024, and R03DK127010 and an AARP Quality Measure Innovation Grant. Dr Pasquel was partially supported by NIDDK grant P30DK111024 and National Institute of General Medical Sciences grant 1K23GM128221. Funding Information: Conflict of Interest Disclosures: Dr. Cusi reported receiving research support as a principal investigator for the University of Florida from Cirius Therapeutics, Echosens, Inventiva, Novartis, Novo Nordisk, Poxel, and Zydus Pharmaceuticals and is a consultant for Allergan, Altimmune, Arrowhead Pharmaceuticals Inc, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Coherus BioSciences, Eli Lilly and Company, Fractyl Laboratories Inc, Hanmi Pharmaceutical Co, Genentech, Gilead Sciences Inc, Intercept Pharmaceuticals, Janssen, Pfizer, ProSciento, Madrigal Pharmaceuticals, and Novo Nordisk. Dr Pasquel reported receiving research support for Emory University from Dexcom, Merck, and Insulet and personal fees from Boehringer Ingelheim, AstraZeneca, Eli Lilly and Co, and Merck outside the submitted work. Dr. Miller reported receiving grant funding through Emory University from Gilead Sciences and serves on an advisory board for AbbVie. No other disclosures were reported.",

year = "2022",

month = mar,

day = "18",

doi = "10.1001/jamanetworkopen.2021.42282",

language = "English (US)",

volume = "5",

journal = "JAMA Network Open",

issn = "2574-3805",

publisher = "American Medical Association",

number = "3",

}

TY - JOUR

T1 - Association of Obesity, Diabetes, and Alcohol Use with Liver Fibrosis among US Adults with Hepatitis C Virus Infection

AU - Migdal, Alexandra L.

AU - Jagannathan, Ram

AU - Qayed, Emad

AU - Cusi, Kenneth

AU - McCoy, Rozalina G.

AU - Pasquel, Francisco J.

AU - Miller, Lesley S.

N1 - Funding Information: Funding/Support: Dr Cusi was partially supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grants R01DK120331 and 1U01DK108320. Dr McCoy was partially supported by NIDDK grants K23DK114497, P30DK111024, and R03DK127010 and an AARP Quality Measure Innovation Grant. Dr Pasquel was partially supported by NIDDK grant P30DK111024 and National Institute of General Medical Sciences grant 1K23GM128221. Funding Information: Conflict of Interest Disclosures: Dr. Cusi reported receiving research support as a principal investigator for the University of Florida from Cirius Therapeutics, Echosens, Inventiva, Novartis, Novo Nordisk, Poxel, and Zydus Pharmaceuticals and is a consultant for Allergan, Altimmune, Arrowhead Pharmaceuticals Inc, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Coherus BioSciences, Eli Lilly and Company, Fractyl Laboratories Inc, Hanmi Pharmaceutical Co, Genentech, Gilead Sciences Inc, Intercept Pharmaceuticals, Janssen, Pfizer, ProSciento, Madrigal Pharmaceuticals, and Novo Nordisk. Dr Pasquel reported receiving research support for Emory University from Dexcom, Merck, and Insulet and personal fees from Boehringer Ingelheim, AstraZeneca, Eli Lilly and Co, and Merck outside the submitted work. Dr. Miller reported receiving grant funding through Emory University from Gilead Sciences and serves on an advisory board for AbbVie. No other disclosures were reported.

PY - 2022/3/18

Y1 - 2022/3/18

UR - http://www.scopus.com/inward/record.url?scp=85126726769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126726769&partnerID=8YFLogxK

U2 - 10.1001/jamanetworkopen.2021.42282

DO - 10.1001/jamanetworkopen.2021.42282

M3 - Article

C2 - 35302636

AN - SCOPUS:85126726769

SN - 2574-3805

VL - 5

JO - JAMA Network Open

JF - JAMA Network Open

IS - 3

M1 - e2142282

ER -

Association of Obesity, Diabetes, and Alcohol Use with Liver Fibrosis among US Adults with Hepatitis C Virus Infection

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this